Press release
Human Umbilical Vein Endothelial Cells (HUVEC) Market Is Set To Register A CAGR Of 10% by 2031
Growth of the market remained consistent across the COVID-19 pandemic, although initial shocks were experienced in the first half of 2020, attributed to reduced hospital visits amid fears of contracting the novel coronavirus infection. Future prospects are extremely lucrative, especially across emerging economies across Asia as spending on healthcare infrastructure augments.
๐๐ผ๐๐ป๐น๐ผ๐ฎ๐ฑ ๐ฎ ๐ฆ๐ฎ๐บ๐ฝ๐น๐ฒ ๐๐ผ๐ฝ๐ ๐ผ๐ณ ๐ง๐ต๐ถ๐ ๐ฅ๐ฒ๐ฝ๐ผ๐ฟ๐: -https://www.factmr.com/connectus/sample?flag=S&rep_id=6216?PJ
๐๐ผ๐บ๐ฝ๐ฒ๐๐ถ๐๐ถ๐๐ฒ ๐๐ฎ๐ป๐ฑ๐๐ฐ๐ฎ๐ฝ๐ฒ
The HUVEC landscape appears highly consolidated, marked by the presence of a handful of service providers across prominent geographies. These players primarily concentrate on offering high-grade product offerings as their primary expansion strategy.
In December 2020, Corning Inc. launched the Corningยฎ X-SERIESยฎ cell processing platform which delivers fast, sterile, automated and efficient processing of human blood and blood products to obtain purified populations of immune cells for gene therapy applications
Thermo Fisher Scientific offers the GibcoTM HUVEC Adherent Cell Culture which is cryopreserved and tested for Hepatitis B (HBV), Hepatitis C (HCV), sterility testing (bacterial & fungi), mycoplasma, HIV-1 and as a growth performance assay
Lonza Group AG
PromoCell- Human Centered Science
Merck & Co. KGaA
Thermo Fisher Scientific
Lifeline
Corning Inc.
๐๐ป๐ฑ๐๐๐๐ฟ๐ ๐ง๐ฟ๐ฒ๐ป๐ฑ๐
The HUVEC market is characterized by several noteworthy trends that are influencing its growth. One of these trends is the increasing demand for 3D cell culture models, which better mimic the in vivo microenvironment. Researchers are increasingly using HUVECs in co-culture with other cell types to create complex tissue models for drug testing and disease modeling. This approach allows for more accurate assessments of drug efficacy and safety.
Furthermore, there is a growing interest in the development of advanced cell culture media and supplements optimized for HUVECs. These media formulations are designed to support cell proliferation, maintain cell health, and promote the expression of specific endothelial markers. This trend is driven by the need for consistent and reproducible results in research and drug discovery.
๐๐ฒ๐ ๐ ๐ฎ๐ฟ๐ธ๐ฒ๐ ๐ฆ๐ฒ๐ด๐บ๐ฒ๐ป๐๐ ๐๐ผ๐๐ฒ๐ฟ๐ฒ๐ฑ
๐ง๐๐ฝ๐ฒ
Single Donors of Human Umbilical Vein Endothelial Cells
Pooled Donors of Human Umbilical Vein Endothelial Cells
๐๐ฝ๐ฝ๐น๐ถ๐ฐ๐ฎ๐๐ถ๐ผ๐ป
Human Umbilical Vein Endothelial Cells for Wound Healing
Human Umbilical Vein Endothelial Cells for Angiogenesis
Human Umbilical Vein Endothelial Cells for Tissue Engineering
Human Umbilical Vein Endothelial Cells for Inflammation Treatment
Human Umbilical Vein Endothelial Cells for Oncology
Human Umbilical Vein Endothelial Cells for Other Applications
๐ฅ๐ฒ๐ด๐ถ๐ผ๐ป
North America
U.S.
Canada
Europe
Germany
France
U.K
Italy
Russia
Nordics
Rest of Europe
Asia Pacific
China
Japan
South Korea
India
Australia
Rest of Asia Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
GCC
Turkey
Rest of MEA
๐ฅ๐ฒ๐ฐ๐ฒ๐ป๐ ๐๐ป๐ฑ๐๐๐๐ฟ๐ ๐ก๐ฒ๐๐
Lonza Launches Advanced HUVEC Culture System: Lonza Group AG recently introduced an advanced HUVEC culture system that aims to improve cell health and consistency in research applications. This system includes specialized media and supplements tailored to support HUVEC growth and functionality, addressing the demand for high-quality HUVEC products.
PromoCell Expands HUVEC Product Line: PromoCell expanded its portfolio of HUVEC-related products, including new cryopreserved HUVECs, specialized growth factors, and media formulations. This expansion is designed to meet the increasing demand for reliable and versatile HUVEC products for research applications.
Cell Applications Inc. Collaborates on Vascular Tissue Engineering Project: Cell Applications Inc. entered into a collaboration to provide HUVECs for a vascular tissue engineering project. This project aims to develop functional vascular grafts and vessels using HUVECs, contributing to the advancement of regenerative medicine.
ATCC Announces HUVEC Authentication Services: ATCC announced the availability of HUVEC authentication services to ensure the quality and identity of HUVEC cultures. This initiative aligns with the growing emphasis on cell line authentication and reproducibility in scientific research.
Thermo Fisher Scientific's Investment in HUVEC Research: Thermo Fisher Scientific has invested in research and development efforts aimed at improving HUVEC-based research models. This includes the development of advanced 3D culture systems and the creation of disease-specific HUVEC models for drug screening and personalized medicine.
๐๐ต๐ฎ๐น๐น๐ฒ๐ป๐ด๐ฒ๐ ๐ฎ๐ป๐ฑ ๐ข๐ฝ๐ฝ๐ผ๐ฟ๐๐๐ป๐ถ๐๐ถ๐ฒ๐
The HUVEC market faces both challenges and opportunities. Challenges include ethical considerations surrounding the use of human-derived cells, variations in cell quality, and the need for standardized culture methods to ensure consistent results across research studies. Additionally, the cost of HUVEC products and research materials can be a barrier for some institutions.
However, opportunities for growth in the HUVEC market are abundant. The increasing interest in regenerative medicine and tissue engineering, coupled with the demand for personalized medicine, provides an excellent opportunity for the expansion of HUVEC-based research and product development. The development of advanced cell culture systems and technologies, such as organ-on-a-chip models, presents new avenues for HUVEC research and applications.
๐๐ฒ๐ ๐๐๐๐๐ผ๐บ๐ถ๐๐ฎ๐๐ถ๐ผ๐ป ๐ผ๐ป ๐๐ต๐ถ๐ ๐ฅ๐ฒ๐ฝ๐ผ๐ฟ๐ ๐ณ๐ผ๐ฟ ๐ฆ๐ฝ๐ฒ๐ฐ๐ถ๐ณ๐ถ๐ฐ ๐ฅ๐ฒ๐๐ฒ๐ฎ๐ฟ๐ฐ๐ต ๐ฆ๐ผ๐น๐๐๐ถ๐ผ๐ป๐:https://www.factmr.com/connectus/sample?flag=RC&rep_id=6216
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Human Umbilical Vein Endothelial Cells (HUVEC) Market Is Set To Register A CAGR Of 10% by 2031 here
News-ID: 3268703 • Views: โฆ
More Releases from Fact.MR
2036 Global Freeze-dried Pea Isolates Market Intelligence Report: Technology Shi โฆ
The global freeze-dried pea isolates market is projected to witness robust expansion through the next decade as food manufacturers and consumers increasingly seek high-quality, plant-based protein ingredients that support clean-label products and sustainable nutrition. In 2025, the freeze-dried pea isolates market is valued at USD 1.1 billion, and it is expected to reach USD 2.8 billion by 2035, representing an absolute increase of USD 1.7 billion over the forecast period.โฆ
Executive Report: Future of the Global High-concentrated Protein Market - Key Dr โฆ
The global high-concentrated protein market is anticipated to record significant expansion over the next decade as consumer awareness of protein's nutritional benefits rises across food & beverage, Food supplements, sports nutrition, clinical nutrition, and animal feed sectors. Driven by trends toward healthy lifestyles, balanced diets, and functional food formulations, demand for concentrated protein ingredients is expected to further increase as individuals and manufacturers alike prioritise high-quality protein sources.
Industry analyses indicateโฆ
Hydrogen Vehicles Market Forecast 2026-2036: Market Size, Share, Competitive Lan โฆ
The global hydrogen vehicles market is projected to experience substantial growth over the next decade as manufacturers, governments, and consumers increase investments in zero-emission transportation technologies. In 2025, the hydrogen vehicles market is valued at USD 12.5 billion, and it is expected to reach USD 47.8 billion by 2035, reflecting an absolute increase of USD 35.3 billion over the forecast period. This expansion corresponds to a compound annual growth rateโฆ
Motor Soft Starter Market Outlook 2026-2036: Strategic Trends, Innovation Driver โฆ
The motor soft starter market is poised for significant growth over the next decade as industries seek to improve electric motor performance, reduce mechanical stress, and enhance energy efficiency in industrial operations. In 2025, the motor soft starter market is valued at USD 2.8 billion, and it is projected to reach USD 6.9 billion by 2035, representing an absolute increase of USD 4.1 billion over the forecast period. This growthโฆ
More Releases for HUVEC
Human Platelet Lysate Market Expanding at a CAGR of 6.5% by 2035 | Asia Pacific, โฆ
The global human platelet lysate market is projected to grow from approximately USD 160.0 million in 2025 to around USD 300.0 million by 2035, representing a compound annual growth rate (CAGR) of about 6.5% over the forecast period.
Growth is underpinned by increasing adoption of cell therapy solutions, rising demand for xeno-free cell culture media, and expanding applications in regenerative medicine and biotechnology research.
Human platelet lysate (HPL) serves as a high-performanceโฆ
Human Umbilical Vein Endothelial Cells (HUVEC) Market 2028- Analysis And In-Dept โฆ
QY Research has recently published a new report, titled Global Human Umbilical Vein Endothelial Cells (HUVEC) Market Research Report 2022. The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Human Umbilical Vein Endothelial Cells (HUVEC) market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on theโฆ
Human Umbilical Vein Endothelial Cells (HUVEC) Market Will Continue to Boom in t โฆ
The Human Umbilical Vein Endothelial Cells (HUVEC) Market research study is a professional report with premium insights into the size of the business, current patterns, drivers, risks, potential outcomes, and major segments. The Industry Report forecasts the future growth of the market based on precise assumptions. Furthermore, based on input from industry experts, the report provides actionable insights into the Human Umbilical Vein Endothelial Cells (HUVEC) market's future growth toโฆ
Cosmetic Peptide Synthesis Market is projected to expand at a CAGR of 10.7% over โฆ
Growing significance of genomics and proteomics has been contributing to the growth of the global vascular endothelial growth factor (VEGF) market. The market was valued at US$ 195.4 Mn at the end of 2021 and is projected to expand at a CAGR of 10.7% over the forecast period (2022-2032), according to Persistence Market Research.
Tumor cells, keratinocytes, platelets, renal mesangial cells, and macrophages are among the cells that produce VEGF. VEGF'sโฆ
Endothelial Cells Latest Trends and Forecast Analysis up to 2031
250 Pages Endothelial Cells Market Survey by Fact MR, A Leading Business and Competitive Intelligence Provider
Subtitle โFact MR analysis of Endothelial Cells market provides compelling insights into the factors propelling sales prospects in key segments. It provides an executive-level blueprint of key market players' strategies and analyses their impact on overall growth projections.
According to Fact MRโs recent market research, Endothelial Cells sales to swell at propelled CAGR through 2031, asโฆ
Globle Structured Cabling Market to Grow 2X Through 2031
Award-winning consulting firm Fact.MRโs report on the global human umbilical vein endothelial cells (HUVEC) market forecasts a healthy growth trajectory for the 2021-2031 forecast period. According to the study, rapid advancements in biotechnology and genetic engineering are opening up new growth avenues for advanced disease treatment, particularly across areas such as oncology.
As per data published by GLOBOCAN, global cancer burden rose to 19.3 million cases, while associated fatalities increased toโฆ
